Enanta Pharmaceuticals (NASDAQ: ENTA)
Enanta Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Enanta Pharmaceuticals Company Info
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.
News & Analysis
Why Shares of Enanta Pharmaceuticals Are Dropping Tuesday
The company saw a slight revenue decline in its fiscal 2023 third-quarter earnings report.
Enanta Pharmaceuticals' Q4 Results Pulled Down by AbbVie's Sinking HCV Sales
The small drugmaker depends on royalties from HCV drug Mavyret. And those sales aren't as strong as they used to be.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.